Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 2432 total matches.
In Brief: Empagliflozin (Jardiance) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
to improve renal outcomes (see
Table 1). The SGLT2 inhibitors ertugliflozin (Steglatro)
and bexagliflozin ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of
sustained eGFR decline, end-stage kidney disease,
cardiovascular death, and hospitalization in adults with
chronic kidney disease (CKD) at risk of progression.
It is also approved to improve glycemic control in
patients ≥10 years old with type 2 diabetes, to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in adults with HF, and to reduce
the risk of cardiovascular death in adults with type...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):183-4 doi:10.58347/tml.2023.1689c | Show Introduction Hide Introduction
Comparison Chart: Antiviral Drugs for Influenza for 2023-2024 (online only)
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
≥1 year old $27.00 158.00
Peramivir – Rapivab (BioCryst)
200 mg/20 mL single-use vials
IV
FDA ...
View the Comparison Chart: Antiviral Drugs for Influenza for 2023-2024
Med Lett Drugs Ther. 2023 Nov 13;65(1689):e1-6 doi:10.58347/tml.2023.1689e | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
with an NSAID,
colchicine, or a systemic corticosteroid. An IL-1 inhibitor can
be used when these drugs ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
AD-Detect — A Blood Test for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
) can improve
their accuracy.1,2
In addition to AD-Detect, Quest offers a blood
test for the ApoE ...
AD-Detect (Quest), a blood test to evaluate
Alzheimer's disease risk, is being marketed directly
to consumers. It has not been cleared or approved
by the FDA (laboratory-developed tests like this
one currently do not need FDA authorization to be
marketed).
Med Lett Drugs Ther. 2023 Oct 30;65(1688):175-6 doi:10.58347/tml.2023.1688b | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
x 1 dose,
then 200 mg PO 12 hrs later on
day 1, followed by 200 mg PO bid
$16.20
937.80 ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
and Moderna
vaccines are no longer authorized for use in the US.1-3
THE NEW VACCINES – The new formulations ...
New 2023-2024 formulations of the mRNA COVID-19
vaccines manufactured by Pfizer/BioNTech
(Comirnaty) and that more
closely target currently circulating variants have
been licensed by the FDA for use in persons ≥12 years
old and made available under FDA Emergency Use
Authorizations (EUAs) for use in persons 6 months
to 11 years old. The bivalent (original and Omicron
BA.4/5) formulations of the Pfizer and Moderna
vaccines are no longer authorized for use in the US.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):167-8 doi:10.58347/tml.2023.1687c | Show Introduction Hide Introduction
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
is recommended for everyone ≥6 months
old without a contraindication.1,2 Influenza vaccines
that are available ...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Med Lett Drugs Ther. 2023 Oct 16;65(1687):161-6 doi:10.58347/tml.2023.1687a | Show Introduction Hide Introduction
Nalmefene Nasal Spray (Opvee) for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
(see Table 2).1-3
ADVERSE EFFECTS ― The most common adverse
effects of nalmefene nasal spray ...
The FDA has approved an intranasal formulation of
the opioid antagonist nalmefene (Opvee – Indivior) for
emergency treatment of known or suspected opioid
overdose in persons ≥12 years old. Nalmefene, which
is available by prescription, is the second opioid
antagonist to become available as a nasal spray
for this indication; the first was naloxone, which is
now available for sale over the counter (Narcan, and
generic). Other nasal spray formulations of naloxone
and injectable formulations of nalmefene and
naloxone are available by prescription (see Table 2).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):166-7 doi:10.58347/tml.2023.1687b | Show Introduction Hide Introduction
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
, the primary endpoint, was 31.9 months in the
quizartinib arm and 15.1 months in the placebo arm ...
The FDA has approved the oral kinase inhibitor
quizartinib (Vanflyta – Daiichi Sankyo) for use
in combination with standard cytarabine and
anthracycline induction and cytarabine consolidation,
and as maintenance monotherapy following
consolidation chemotherapy in adults with FLT3
internal tandem duplication (ITD)-positive, newly-diagnosed
acute myeloid leukemia (AML).
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e169-70 doi:10.58347/tml.2023.1687d | Show Introduction Hide Introduction
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Oct 16, 2023 (Issue 1687)
0, 2nd at week 3, and 3rd ?8 weeks after dose 2
1 previous Pfizer dose: 1 3-mcg dose ?3 weeks later ...
View the Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines
Med Lett Drugs Ther. 2023 Oct 16;65(1687):e1 doi:10.58347/tml.2023.1687e | Show Introduction Hide Introduction